IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024
IPA (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, will report its financial results and recent business highlights for the second quarter of fiscal year 2025 on December 10, 2024. The company will host a live conference call and webcast at 10:30 AM ET on the same day to discuss the results and provide a corporate update. The call will include a question-and-answer period with ImmunoPrecise management. Participants can join via provided dial-in numbers or access the webcast through a link on the company's IR page. For more details, visit the company's profile on www.sedarplus.com and www.sec.gov.
IPA (NASDAQ: IPA), un'azienda di ricerca e tecnologia bioterapeutica basata sull'IA, comunicherà i suoi risultati finanziari e i recenti punti salienti aziendali per il secondo trimestre dell'anno fiscale 2025 il 10 dicembre 2024. L'azienda organizzerà una chiamata in conferenza dal vivo e una trasmissione web alle 10:30 AM ET lo stesso giorno per discutere i risultati e fornire un aggiornamento aziendale. La chiamata includerà un periodo di domande e risposte con la direzione di ImmunoPrecise. I partecipanti possono unirsi tramite i numeri di accesso forniti o accedere alla trasmissione web tramite un link nella pagina IR dell'azienda. Per ulteriori dettagli, visita il profilo dell'azienda su www.sedarplus.com e www.sec.gov.
IPA (NASDAQ: IPA), una empresa de investigación y tecnología bioterapéutica impulsada por IA, informará sobre sus resultados financieros y los aspectos destacados recientes del negocio para el segundo trimestre del año fiscal 2025 el 10 de diciembre de 2024. La empresa llevará a cabo una llamada de conferencia en vivo y una transmisión web a las 10:30 AM ET el mismo día para discutir los resultados y proporcionar una actualización corporativa. La llamada incluirá un período de preguntas y respuestas con la gerencia de ImmunoPrecise. Los participantes pueden unirse a través de los números de acceso proporcionados o acceder a la transmisión web a través de un enlace en la página IR de la empresa. Para más detalles, visita el perfil de la empresa en www.sedarplus.com y www.sec.gov.
IPA (NASDAQ: IPA)는 인공지능 기반의 생물의학 연구 및 기술 회사로서, 2025 회계연도 2분기의 재무 결과 및 최근 사업 하이라이트를 2024년 12월 10일에 발표할 예정입니다. 회사는 같은 날 동부 표준시 기준 오전 10시 30분에 실시간 컨퍼런스 콜 및 웹캐스트를 개최하여 결과를 논의하고 기업 업데이트를 제공할 것입니다. 이 통화에는 ImmunoPrecise 경영진과의 질문과 답변 시간이 포함될 것입니다. 참가자는 제공된 전화번호를 통해 접속하거나 회사 IR 페이지의 링크를 통해 웹캐스트에 접근할 수 있습니다. 자세한 내용은 www.sedarplus.com 및 www.sec.gov에서 회사 프로필을 방문해 주십시오.
IPA (NASDAQ: IPA), une entreprise de recherche et de technologie biothérapeutique axée sur l'IA, annoncera ses résultats financiers et les faits marquants récents de ses activités pour le deuxième trimestre de l'exercice 2025 le 10 décembre 2024. L'entreprise organisera une conférence téléphonique en direct et un webinaire le même jour à 10h30 ET pour discuter des résultats et fournir une mise à jour de l'entreprise. L'appel comprendra une période de questions-réponses avec la direction d'ImmunoPrecise. Les participants peuvent se joindre via les numéros de composition fournis ou accéder au webinaire via un lien sur la page IR de l'entreprise. Pour plus de détails, visitez le profil de l'entreprise sur www.sedarplus.com et www.sec.gov.
IPA (NASDAQ: IPA), ein KI-gesteuertes biotherapeutisches Forschungs- und Technologieunternehmen, wird am 10. Dezember 2024 seine finanziellen Ergebnisse und aktuelle Geschäftshighlights für das zweite Quartal des Geschäftsjahres 2025 bekannt geben. Das Unternehmen wird am selben Tag um 10:30 Uhr ET eine Live-Konferenzschaltung und ein Webcast veranstalten, um die Ergebnisse zu diskutieren und ein Unternehmensupdate zu geben. Der Anruf wird eine Frage-und-Antwort-Runde mit dem Management von ImmunoPrecise beinhalten. Teilnehmer können sich über die bereitgestellten Einwahlnummern einwählen oder über einen Link auf der IR-Seite des Unternehmens auf den Webcast zugreifen. Für weitere Informationen besuchen Sie bitte das Unternehmensprofil auf www.sedarplus.com und www.sec.gov.
- None.
- None.
The Company to host an earnings conference call via webcast
Conference Call and Webcast Details
The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Tuesday, December 10, 2024, at 10:30AM ET.
The conference call will be webcast live and available for replay via a link provided in the Events section of the Company’s IR pages at https://ir.ipatherapeutics.com/events-and-presentations/default.aspx.
***Participant Dial-In Details***
Participants call one of the allocated dial-in numbers (below) and advise the Operator of either the Conference ID 3224490 or Conference Name.
***Webcast Details***
Attendee URL:
https://events.q4inc.com/attendee/560160139
Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization.
Anyone listening to the call is encouraged to read the company's periodic reports available on the company’s profile at www.sedarplus.com and www.sec.gov, including the discussion of risk factors and historical results of operations and financial condition in those reports.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241203734695/en/
Investor Relations Contact
investors@ipatherapeutics.com
Source: ImmunoPrecise Antibodies Ltd.
FAQ
When will IPA report its financial results for Q2 FY 2025?
What time is IPA's earnings conference call for Q2 FY 2025?
How can I access IPA's earnings conference call for Q2 FY 2025?
Where can I find more details about IPA's financial results and business highlights?
